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The reported incidence of renal calculi complicating Zonisamide (ZNS) therapy for epilepsy ranges from 0.2 to 4.4%.'"^ Typically this complication leads to discontinuation of the drug. For patients uniquely responsive to Zonisamide, the benefits of continued treatment may outweigh the risk of calculus recurrence. We report three patients who developed nephrolithiasis but continued ZNS treatment without recurrence of calculi. have also been linked to nephrolithiasis. AZA, TPM and ZNG all inhibit carbonic anhydrase, although the inhibitory potency of ZNS is 100 fold less than that of AZA.'
Nephrolithiasis during acetazolamide therapy has been attributed to alkalinization of the urine, increased calcium excretion, and decreased urinary citrate, which inhibits calcium Since the recurrence rate of renal calculi during continued ZNS treatment is unknown, the yield and cost-effectiveness of these surveillance tests cannot be assessed. Increased fluid intake has proven efficacy in preventing recurrence of nephrolithiasis from any cause, decreasing recurrence by 50% in one study.' Citrate supplementation is another rational strategy, given the hypocitraturia documented in acetazolamide treatment, but hydration alone may be adequate. Dietary calcium should not be restricted, as this may promote bone loss.' Consultation with a nephrologist may identify other modifiable patient-specific factors that could affect recurrence risk, such as hypercalciuria.
These cases illustrate that some patients who develop nephrolithiasis during ZNS treatment may tolerate continued long-term use of ZNS without recurrence. In patients with distinctive responsiveness to ZNS, the development of renal calculi need not be an absolute indication to discontinue treatment. Daily fluid intake should be increased to decrease risk of recurrence.
